Pyrazolo[1,5-a]pyrimidine 4h

SKU: orb1306546

Description

This morpholine-containing pyrazolo[1,5-a]pyrimidine derivative is a selective adenosine A2A receptor antagonist. It exhibits neuroprotective properties, as demonstrated in preclinical in vivo models for Parkinson's and Huntington's disease research.

Key Properties

• CAS Number: 597544-21-3
• MW: 401.46
• Purity: 99.01%
• Formula: C₂₃H₂₃N₅O₂
• SMILES: O(CCN1CCOCC1)C2=CC=C(C3=CN4C(=C(C=N4)C=5C=CN=CC5)N=C3)C=C2
• Target: Others
• Solubility: DMSO:25 mg/mL (62.27 mM)

Bioactivity

• In Vivo:
  Only Parthenolide, the HDAC inhibitor with anti-inflammatory features, displayed a potent anti-apoptotic effect in Phb1 KO hepatocytes. Indeed, TSA and Parthenolide-treated hepatocytes showed increased levels of FXR, and reduced levels of CYP7A1, HDAC4, TNFα, TRAIL and Bax suggesting a less toxic effect of bile acids as a results of specific HDAC inhibition, resulting in the attenuation of the Phb1 KO hepatocytes apoptotic response. Importantly, Parthenolide exerts a protective effect from the liver injury after BDL in Phb1 KO mice. Indeed, Parthenolide treatment results in a reduction of the mortality rate of this mice after BDL associated with a lower apoptotic response as revealed by a reduction of necrotic areas, Tunel-staining, as well as decreased ALT (8431±957 vs.4225±210 U/L) and AST (4805±300 vs.2242±438 U/L) activities compared to control Phb1 KO mice.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Pyrazolo[1,5 a]pyrimidine 4h, Pyrazolo[1,5a]pyrimidine 4h, Pyrazolo[1,5-a]pyrimidine 4h

Compound Identifiers

PubChem CID

5329453